In contrast, although preclinical data have suggested PI3K pathway alterations to be predictive of anti-tumor activity in response to PI3K/Akt/mTOR inhibitors, no consensus was yet attained in early clinical trials [30, 32–35]. Here, MTOR is linked to neoplasm.